Investor Relations

Company Description

News

Financial Reports

Financial Calendar

Presentations

The Share

New Issues

Corporate Governance

IR Contact

DigniCap Delta study underway in Brindisi, Italy

Dignitana announces that Antonio Perrino Hospital in Brindisi, Italy has initiated a clinical study of the DigniCap Delta Scalp Cooling System which features advanced thermoelectric cooling. The FDA-cleared DigniCap Scalp Cooling System minimizes hair loss from chemotherapy for cancer patients with solid tumors such as breast, prostate, and gynecological cancers.

Files for download
Dignitana Release - wkr0006.pdf

Led by Dr. Dario Loparco, Breast Unit psycho-oncologist and DigniCap protocol manager at the ASL Brindisi Breast Unit,  the study is focused on breast cancer patients being treated with one of the most challenging chemotherapy regimens for hair retention -- epirubicin, cyclophosphamide and docetaxel (EC-T).

“DigniCap is quickly becoming standard of care in Italy and we are proud to have offered this life-changing therapy since 2015.  In a disease where so much is out of their control, cancer patients need to have the opportunity to preserve their hair during chemotherapy – and DigniCap gives them that choice,“ said Dr. Loparco.

Dr. Loparco and the oncology team at Antonio Perrino Hospital have published three previous clinical studies using the legacy DigniCap C3 system. Those studies demonstrated DigniCap success rates of 71 percent, 71.7 percent, and 72.8 percent using a variety of chemotherapy regimens in breast cancer patients.

Recognized internationally as a standard of care and quality of life advancement for cancer patients, scalp cooling is listed as a treatment recommendation in the clinical practice guidelines published by European Society for Medical Oncology (ESMO), National Comprehensive Cancer Network® (NCCN) and Cancer Australia.

For More Information Contact 

Melissa Bourestom, Chief Communications Officer,  melissa.bourestom@dignitana.com  +1 469-518-5031

About Dignitana

Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001.  Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States.  Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com.